<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Regorafenib</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08896</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumours. <span class="caps">FDA</span> approved on September 27, 2012.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08896/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08896/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08896.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08896.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08896.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08896.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08896.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08896">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Stivarga </td><td>Bayer HealthCare Pharmaceuticals</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents">Antineoplastic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>755037-03-7</td></tr><tr><th>Weight</th><td>Average: 482.815<br>Monoisotopic: 482.076880893</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>15</sub>ClF<sub>4</sub>N<sub>4</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>FNHKPVJBJVTLMP-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organooxygen Compounds</td></tr><tr><th>Class</th><td>Ethers</td></tr><tr><th>Subclass</th><td>Diarylethers</td></tr><tr><th>Direct parent</th><td>Diarylethers</td></tr><tr><th>Alternative parents</th><td>Pyridinecarboxamides; Phenol Ethers; Fluorobenzenes; Chlorobenzenes; Aryl Fluorides; Aryl Chlorides; Secondary Carboxylic Acid Amides; Enolates; Polyamines; Carboxylic Acids; Organofluorides; Organochlorides; Alkyl Fluorides</td></tr><tr><th>Substituents</th><td>pyridinecarboxamide; pyridine carboxylic acid or derivative; phenol ether; fluorobenzene; chlorobenzene; pyridine; aryl chloride; aryl halide; benzene; aryl fluoride; secondary carboxylic acid amide; carboxamide group; carboxylic acid; carboxylic acid derivative; enolate; polyamine; organofluoride; organochloride; organohalogen; amine; organonitrogen compound; alkyl halide; alkyl fluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.</td></tr><tr><th>Pharmacodynamics</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Mechanism of action</th><td>Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and M-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl at concentrations of regorafenib that have been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model, and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some for human colorectal carcinoma.</td></tr><tr><th>Absorption</th><td>Cmax = 2.5 &#956;g/mL;
Tmax = 4 hours; 
AUC = 70.4 &#956;g*h/mL; 
Cmax, steady-state = 3.9 &#956;g/mL;
AUC, steady-state = 58.3 &#956;g*h/mL;
The mean relative bioavailability of tablets compared to an oral solution is 69% to 83%.</td></tr><tr><th>Volume of distribution</th><td><p>Regorafenib undergoes enterohepatic circulation with multiple plasma concentration peaks observed across the 24-hour dosing interval.</p></td></tr><tr><th>Protein binding</th><td>Regorafenib is highly bound (99.5%) to human plasma proteins.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Regorafenib is metabolized by CYP3A4 and UGT1A9. The main circulating metabolites of regorafenib measured at steady-state in human plasma are M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl), both of them having similar in vitro pharmacological activity and steady-state concentrations as regorafenib. M-2 and M-5 are highly protein bound (99.8% and 99.95%, respectively).</p></td></tr><tr><th>Route of elimination</th><td>Approximately 71% of a radiolabeled dose was excreted in feces (47% as parent compound, 24% as metabolites) and 19% of the dose was excreted in urine (17% as glucuronides) within 12 days after administration of a radiolabeled oral solution at a dose of 120 mg.</td></tr><tr><th>Half life</th><td>Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);  </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>The most common adverse reactions (&#8805;20%) are asthenia/fatigue, HFSR, diarrhea, decreased appetite/food intake, hypertension, mucositis, dysphonia, and infection, pain (not otherwise specified), decreased weight, gastrointestinal and abdominal pain, rash, fever, and nausea</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9649</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.851</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5138</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5086</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7141</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9359</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8938</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6569</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8212</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5341</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.6168</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6171</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9145</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.637</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7339</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.6629</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8143
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8684
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7885 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9488
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6415
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>40 mg </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Strong CYP3A4 inducers may decrease levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Strong CYP3A4 inhibitors may increase levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB00762">Irinotecan</a></td><td>Regorafenib may increase levels of irinotecan, a UGT1A1 substrate. </td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Strong CYP3A4 inducers may decrease levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Strong CYP3A4 inducers may decrease levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Strong CYP3A4 inducers may decrease levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>Strong CYP3A4 inducers may decrease levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Strong CYP3A4 inhibitors may increase levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of regorafenib. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>When taken with a high-fat meal, AUC increased by 48% and decreased mean AUC of M2 and M5 metabolites by 20% and 51% respectively.</li></ul></td></tr></tbody></table>